Next-Generation Cell Isolation Partnership Expands Global Access to Gene Therapy Tools
ANN ARBOR, Mich., September 25, 2025 — Cayman Chemical, a global provider of life science research tools, and Akadeum...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
ANN ARBOR, Mich., September 25, 2025 — Cayman Chemical, a global provider of life science research tools, and Akadeum...
SAN DIEGO, Sept. 25, 2025 (cGxP.wire) – Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, announced...
CHARLESTOWN, Mass., Sept. 23, 2025 — Solid Biosciences has entered a non-exclusive licensing agreement with Kinea Bio to utilize...
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
GRAND CAYMAN, Cayman Islands, Sept. 11, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN), a clinical-stage biotechnology company developing RNA...
